CHI Advisors
Latest statistics and disclosures from CHI Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PLRX, Acelyrin, VECT, CGEM, RPTX, and represent 69.30% of CHI Advisors's stock portfolio.
- Added to shares of these 10 stocks: Acelyrin (+$56M), KROS (+$5.7M), IRON (+$5.6M), LABD, PLRX, RARE, BDTX, IKNA, LRMR, CGEM.
- Started 8 new stock positions in Acelyrin, Freeline Therapeutics Holdings, IRON, BDTX, HOOK, GRPH, RARE, LABD.
- Reduced shares in these 10 stocks: Prometheus Biosciences (-$103M), VECT (-$42M), CRVS, KDNY, KZR, Freeline Therapeutics Hldgs, RLYB, DTIL, INZY, TRDA.
- Sold out of its positions in KDNY, TRDA, Freeline Therapeutics Hldgs, KZR, ONCR, Prometheus Biosciences.
- CHI Advisors was a net seller of stock by $-71M.
- CHI Advisors has $332M in assets under management (AUM), dropping by -12.53%.
- Central Index Key (CIK): 0001791468
Tip: Access up to 7 years of quarterly data
Positions held by CHI Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for CHI Advisors
CHI Advisors holds 25 positions in its portfolio as reported in the June 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Pliant Therapeutics (PLRX) | 17.7 | $59M | +8% | 3.2M | 18.12 |
|
| Acelyrin | 16.8 | $56M | NEW | 2.7M | 20.90 |
|
| Vectivbio Hldg Ord Shs (VECT) | 14.2 | $47M | -47% | 2.8M | 16.87 |
|
| Cullinan Oncology (CGEM) | 11.1 | $37M | 3.4M | 10.76 |
|
|
| Repare Therapeutics Ord (RPTX) | 9.6 | $32M | 3.0M | 10.58 |
|
|
| Keros Therapeutics (KROS) | 4.9 | $16M | +54% | 402k | 40.18 |
|
| Ikena Oncology (IKNA) | 4.2 | $14M | +27% | 2.1M | 6.56 |
|
| Compass Therapeutics (CMPX) | 2.7 | $9.0M | 2.8M | 3.18 |
|
|
| Larimar Therapeutics (LRMR) | 2.6 | $8.7M | +24% | 3.4M | 2.55 |
|
| 2seventy Bio Common Stock (TSVT) | 2.6 | $8.6M | 852k | 10.12 |
|
|
| Inozyme Pharma (INZY) | 2.0 | $6.7M | -10% | 1.2M | 5.57 |
|
| Omega Therapeutics Common Stock (OMGA) | 1.8 | $5.9M | 1.1M | 5.60 |
|
|
| Disc Medicine (IRON) | 1.7 | $5.6M | NEW | 125k | 44.40 |
|
| Direxion Shs Etf Tr Daily S&p Biotec (LABD) | 1.4 | $4.7M | NEW | 325k | 14.37 |
|
| Orchard Therapeutics Spon Ads New (ORTX) | 1.2 | $3.9M | -3% | 756k | 5.21 |
|
| Ultragenyx Pharmaceutical (RARE) | 1.2 | $3.9M | NEW | 85k | 46.13 |
|
| Black Diamond Therapeutics (BDTX) | 1.1 | $3.8M | NEW | 750k | 5.05 |
|
| Rallybio Corp (RLYB) | 0.9 | $3.1M | -28% | 543k | 5.66 |
|
| Ovid Therapeutics (OVID) | 0.9 | $2.8M | 865k | 3.28 |
|
|
| Syros Pharmaceuticals Com New (SYRS) | 0.7 | $2.4M | 767k | 3.15 |
|
|
| Precision Biosciences Ord (DTIL) | 0.3 | $844k | -53% | 1.6M | 0.53 |
|
| Hookipa Pharma Inc equity (HOOK) | 0.2 | $694k | NEW | 789k | 0.88 |
|
| Graphite Bio (GRPH) | 0.2 | $600k | NEW | 231k | 2.60 |
|
| Corvus Pharmaceuticals (CRVS) | 0.1 | $458k | -91% | 200k | 2.29 |
|
| Freeline Therapeutics Hldgs Sponsored Ads | 0.0 | $56k | NEW | 22k | 2.58 |
|
Past Filings by CHI Advisors
SEC 13F filings are viewable for CHI Advisors going back to 2019
- CHI Advisors 2023 Q2 restated filed Aug. 22, 2023
- CHI Advisors 2023 Q2 filed Aug. 11, 2023
- CHI Advisors 2023 Q1 filed May 11, 2023
- CHI Advisors 2022 Q4 filed Feb. 13, 2023
- CHI Advisors 2022 Q3 filed Nov. 9, 2022
- CHI Advisors 2022 Q2 filed Aug. 12, 2022
- CHI Advisors 2022 Q1 filed May 16, 2022
- CHI Advisors 2021 Q4 filed Feb. 11, 2022
- CHI Advisors 2021 Q3 filed Nov. 15, 2021
- CHI Advisors 2021 Q2 filed Aug. 11, 2021
- CHI Advisors 2021 Q1 filed May 14, 2021
- CHI Advisors 2020 Q4 filed Feb. 12, 2021
- CHI Advisors 2020 Q3 filed Nov. 12, 2020
- CHI Advisors 2020 Q2 restated filed Aug. 17, 2020
- CHI Advisors 2020 Q2 filed Aug. 12, 2020
- CHI Advisors 2020 Q1 filed May 14, 2020